Transforming the future of aging and neurodegenerative disease treatment by developing gene therapies that restore youthful cellular function. Unlike conventional treatments that only manage symptoms, its tissue-specific gene therapies use partial cellular reprogramming to reset gene expression, directly reversing the biological processes that drive Alzheimer’s and other age-related diseases.
With a $550B market opportunity, an aging global population, and growing demand for disease-modifying treatments, the company is positioned at the forefront of the longevity and regenerative medicine revolution. Its breakthrough therapies have demonstrated significant cognitive restoration in preclinical models, offering a potentially curative approach to neurodegeneration—a massive unmet need in the healthcare industry.
Backed by exclusive partnerships with world-renowned researchers, a strong intellectual property portfolio, and a clear regulatory path toward clinical trials, the company is raising $10M to advance IND-enabling studies, GMP manufacturing, and further pipeline development. This is a rare opportunity to invest early in a high-impact biotech with first-mover advantage in a trillion-dollar industry.
View the deck through the link below. Some unique identifiers have been removed. For access to detailed materials, please reach to us or your point of contact, as full decks are only shared upon request to maintain confidentiality and exclusivity.
View Pitch Deck